Project Grant R01HL175960
Award Date
6/1/25
Completion Date
3/31/29
Dollars Obligated
$707K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Arlington, TX 76019, USA
Similar Awards
This $580,863 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Program (CFDA 93.837), supports research to develop improved cardiac regenerative therapies using engineered human cardiac organoids. The key products and services being delivered include: Optimizing the electrical properties and surface roughness of silicon nanowires incorporated into the cardiac organoids to enhance their interaction with human pluripotent stem...
This $866,240 National Institutes of Health National Heart, Lung and Blood Institute project grant funds the development of an innovative ablation system for inoperable hypertrophic cardiomyopathy patients at the University of Texas at Arlington from September 1, 2022 to August 31, 2025. The university researchers aim to design a controllable, localized ablation method to replace alcohol ablation and its risks. They will develop a collagenase-coated, doxorubicin-loaded degradable nanoparticle...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a flexible bioelectronic microarchitecture that integrates a capillary-like delivery network and a tissue-like sensing network to improve cardiac tissue engineering. The $488,026 award supports the creation of a system that can efficiently deliver media and provide real-time physiological feedback to enhance the development of...
This $262,138 Project Grant award from the National Science Foundation's Engineering program (CFDA 47.041) supports research at the University of Houston to investigate the mechanisms of cardiac fibrosis, a type of scarring in the heart that leads to impaired function. The key objectives are to: 1) determine the role of the endothelial-mesenchymal transition in cardiac fibrosis, and 2) develop a 3D cardiac fibrosis model to study tissue remodeling. The research will leverage a...
The U.S. National Heart, Lung, and Blood Institute (NHLBI) awarded a $498,991.40 Project Grant to the University of Arkansas under the Cardiovascular Diseases Research (CFDA 93.837) federal grant program. The funding supports the development of microphysiological systems to study hypoxic cardiac injury resulting from acute myocardial infarction and ischemia-reperfusion injury. The research aims to engineer microfluidic devices to precisely control oxygen levels and investigate how oxygen...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $156,600 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The University of Texas Southwestern Medical Center (UT Southwestern). The 5-year grant will support research to define the role of the PHF7 protein in driving cardiac reprogramming and improving heart function following a myocardial infarction. Specifically, the project aims to: 1) Characterize...
The U.S. National Heart, Lung, and Blood Institute (NHLBI) awarded a $989,908 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Nevada, Las Vegas (UNLV). This 4-year grant supports research to evaluate the efficacy of Wnt11-treated mesenchymal stem cells (MSCs) for improving cardiac repair following myocardial infarction. The key objectives are to: 1) examine whether Wnt11 treatment can enhance MSC resistance to apoptosis and improve cell...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $229,971 to the University of North Carolina at Chapel Hill (UNC-CH) to develop and test novel hydrogel patches to prevent air leaks after lung surgery. The patches are designed to be ultra-elastic and instantly adhesive, allowing them to stretch with lung movement and seal perforations in lung tissue. Through in...
This $647,359 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the engineering of biomaterials with controlled biomolecule delivery for cardiovascular applications. The key products and services to be delivered include: Efficient and sustainable delivery of microRNA-145 from a novel biomaterial (PVA-CDI immobilized aminated fucoidan, or PCAF) to smooth muscle cells to induce a contractile...
This $496,367 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop novel approaches for in situ cardiac reprogramming. The key objectives are to: Investigate the mechanism by which a repressor complex inhibits cardiomyocyte gene expression, including testing if knockdown of individual repressors can recapitulate the effects of combined knockdown. Determine if targeting the repressor complex...